Skip to content
PubMed This is a summary of 83 peer-reviewed journal articles Updated
Cardiology

Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease: A Patient Guide

At a Glance

Hereditary atrial tachyarrhythmia-infra-Hisian conduction disease combines fast or irregular atrial rhythms with slowing or blockage in the heart’s lower electrical pathways. Gene-specific monitoring, pacemaker evaluation, and family screening help reduce risk.

Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease is a descriptive medical category for a shared set of symptoms caused by several inherited conditions that affect the heart’s electrical system in two different ways at once. In these conditions, the heart faces a “fast and slow” challenge: the top chambers (the atria) can beat too quickly or irregularly, while the lower electrical pathways—the “infra-Hisian” wiring—gradually slow down or become blocked [1][2]. Because it is a genetic condition, it often appears at a younger age than typical heart rhythm problems and may progress over time, making lifelong, individualized monitoring essential for both you and your family [3].

Understanding your specific genetic mutation is a cornerstone of managing this condition, as different genes can lead to different heart health risks. Pathogenic variants in the SCN5A gene primarily affect the “gates” that control electricity in the heart cells, while variants in PRKAG2 or LMNA can also cause structural changes, such as a thickening or weakening of the heart muscle [4][5]. Knowing your genetic “type” allows your medical team to tailor your care, focusing on whether your condition is purely electrical or if they also need to watch for physical changes in your heart’s structure through regular imaging. Only variants classified as “pathogenic” or “likely pathogenic” are used to definitively guide cascade testing; a “Variant of Uncertain Significance” (VUS) requires further clinical evaluation [6][7].

A primary goal of treatment is to protect you from the risks associated with a slow or blocked heart signal. Fainting, also known as syncope, is a major warning sign that the electricity is not reaching the bottom of the heart, and it is considered a medical emergency that requires immediate evaluation [8]. Depending on your symptoms and documented heart blocks, doctors may recommend a pacemaker to treat dangerous bradycardia; by securing a safe, steady heart rate, they can then more safely use medications or procedures to control the “fast” rhythms in the top chambers without fear of making the “slow” signals worse [1][9].

Living with this diagnosis means looking toward the future for both yourself and your loved ones. Because the condition is hereditary, your diagnosis provides a vital opportunity for “cascade screening,” where your siblings, parents, and children are offered genetic counseling and testing for the pathogenic variant [10]. Even if a family member feels perfectly healthy today, early clinical evaluation and regular check-ups can manage future risks [11]. With a dedicated care team and consistent monitoring, this condition can be managed proactively, allowing you and your family to stay ahead of the changes in your heart [12].

Common questions in this guide

What is hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease?
It is a group of inherited heart rhythm conditions with two problems: the atria may beat too fast or irregularly, while the lower electrical pathways may slow or become blocked. It can begin earlier than many common rhythm problems and may change over time, so long-term follow-up is important.
Which genes can cause this inherited heart rhythm condition?
Pathogenic variants in SCN5A mainly affect the electrical signals in heart cells. Variants in PRKAG2 and LMNA can also affect conduction and may be linked with a thickened or weakened heart muscle, so the gene result helps determine which tests and monitoring are needed.
What does a variant of uncertain significance mean for my family?
A variant of uncertain significance, or VUS, does not by itself establish the inherited cause or determine who should undergo cascade testing. Only pathogenic or likely pathogenic variants are used to definitively guide targeted family testing, so a VUS requires further clinical evaluation.
When might I need a pacemaker?
A pacemaker may be recommended when the heart's lower electrical signals become dangerously slow or blocked, especially with documented heart block or fainting. It maintains a safer, steadier heart rate and can make treatment of fast atrial rhythms safer.
Is fainting with this condition an emergency?
Yes. Fainting can signal that electrical impulses are not reaching the lower chambers of the heart and requires immediate medical evaluation, particularly in someone with known or suspected inherited conduction disease.
Should my children and siblings be tested?
If a pathogenic or likely pathogenic inherited variant is identified, parents, siblings, and children may be offered genetic counseling and targeted testing. Even relatives who feel well may need clinical evaluation and follow-up because heart rhythm problems can develop over time.
How will doctors monitor this condition?
Monitoring may include electrocardiograms to assess conduction and QRS duration, along with echocardiograms or cardiac MRI to look for changes in heart muscle. The schedule depends on your gene, symptoms, ECG findings, and whether structural changes are present.

Get notified when new evidence is published on Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Current Topics of Progressive Cardiac Conduction Disease.

    Sumitomo N, Mori H, Kumamoto T, et al.

    Journal of arrhythmia 2026; (42(3)):e70383 doi:10.1002/joa3.70383.

    PMID: 42368294
  2. 2

    Molecular and genetic insights into progressive cardiac conduction disease.

    Asatryan B, Medeiros-Domingo A

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2019; (21(8)):1145-1158 doi:10.1093/europace/euz109.

    PMID: 31087102
  3. 3

    SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups.

    Baruteau AE, Kyndt F, Behr ER, et al.

    European heart journal 2018; (39(31)):2879-2887 doi:10.1093/eurheartj/ehy412.

    PMID: 30059973
  4. 4

    Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy.

    Wilde AAM, Amin AS

    JACC. Clinical electrophysiology 2018; (4(5)):569-579 doi:10.1016/j.jacep.2018.03.006.

    PMID: 29798782
  5. 5

    Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis.

    Lopez-Sainz A, Dominguez F, Lopes LR, et al.

    Journal of the American College of Cardiology 2020; (76(2)):186-197 doi:10.1016/j.jacc.2020.05.029.

    PMID: 32646569
  6. 6

    Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers.

    Nishiuchi S, Makiyama T, Aiba T, et al.

    Circulation. Cardiovascular genetics 2017; (10(6)) doi:10.1161/CIRCGENETICS.116.001603.

    PMID: 29237675
  7. 7

    Clinical care of family members of patients with dilated cardiomyopathy.

    Verdonschot JAJ, Kaski JP, Asselbergs FW, et al.

    European heart journal 2025; (46(43)):4569-4582 doi:10.1093/eurheartj/ehaf571.

    PMID: 40902100
  8. 8

    [Syncope in prehospital emergency medicine].

    Kill C, Betz S, Bösl E

    Medizinische Klinik, Intensivmedizin und Notfallmedizin 2020; (115(2)):88-93 doi:10.1007/s00063-018-0458-2.

    PMID: 30014263
  9. 9

    Atypical Wenckebach AV Block in the Infra-Hisian Region: Clinical Implications and Management.

    Kaushik A, Jeewooth A, Jaswal A, et al.

    The American journal of case reports 2024; (25()):e946186 doi:10.12659/AJCR.946186.

    PMID: 39702956
  10. 10

    Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications.

    Girolami F, Frisso G, Benelli M, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2018; (19(1)):1-11 doi:10.2459/JCM.0000000000000589.

    PMID: 29176389
  11. 11

    Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.

    Hasselberg NE, Haland TF, Saberniak J, et al.

    European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.

    PMID: 29095976
  12. 12

    Genetic testing in early-onset atrial fibrillation.

    Kany S, Jurgens SJ, Rämö JT, et al.

    European heart journal 2024; (45(34)):3111-3123 doi:10.1093/eurheartj/ehae298.

    PMID: 39028637

This page is for informational purposes only and does not constitute medical advice. It does not replace care from your cardiologist, electrophysiologist, or genetic counselor; fainting or suspected heart block requires immediate medical evaluation.